Exit site infection and peritonitis due to Serratia species in patients receiving peritoneal dialysis: Epidemiology and clinical outcomes

Christy W. H. Au,Desmond Y. H. Yap,Jasper F. W. Chan,Terence P. S. Yip,Tak M. Chan
DOI: https://doi.org/10.1111/nep.13813
2020-12-02
Nephrology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aim</h3><p>To study the epidemiology and clinical outcomes of catheter‐related infections of <i>Serratia</i> species in peritoneal dialysis (PD) patients. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We retrospectively reviewed the patient characteristics, antibiotics susceptibility/resistance patterns and treatment outcomes of exit site infection (ESI) and peritonitis due to <i>Serratia</i> in PD patients during the period of 2004 to 2017. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>One hundred and sixty‐one patients had <i>Serratia</i> ESI, of which 10 (6.2%) progressed to tunnel tract involvement and 11 (6.8%) developed PD peritonitis. Nineteen patients (11.8%) with <i>Serratia</i> ESI failed to respond to medical treatment and required catheter removal. Fifty‐six patients (34.8%) had repeat <i>Serratia</i> ESI, which occurred at 12.9±13.6 months after the previous episode. Twenty‐two patients had <i>Serratia</i> peritonitis, which accounted for 1% of peritonitis during the study period. Ten patients (45.5%) responded to medical treatment while 12 patients (54.5%) required catheter removal. Nine patients (36.4%) failed to resume PD and were converted to long‐term haemodialysis. Two patients had repeat peritonitis at 2 months and 3 years respectively after the initial episode. <i>Serratia</i> species in PD patients showed high rates of resistance to ampicillin, and first‐ and second‐generation cephalosporins, but were generally susceptible to aminoglycosides, carboxy‐/ureido‐penicillins and carbapenems. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Our results suggest that <i>Serratia</i> ESI show low risk of progression to peritonitis and favourable response to medical therapy, while <i>Serratia</i> peritonitis was associated with high rates of catheter removal and peritoneal failure. </p></section>
urology & nephrology
What problem does this paper attempt to address?